- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
- Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
- Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
- Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
- Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
- Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
More ▼
Key statistics
On Thursday, Verrica Pharmaceuticals Inc (VRCA:NMQ) closed at 5.92, -23.66% below its 52-week high of 7.76, set on Jul 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.70 |
---|---|
High | 6.03 |
Low | 5.60 |
Bid | 5.51 |
Offer | 6.18 |
Previous close | 5.65 |
Average volume | 141.14k |
---|---|
Shares outstanding | 42.42m |
Free float | 18.48m |
P/E (TTM) | -- |
Market cap | 251.12m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼